CICR-NAM

DIETARY_SUPPLEMENT2 trials

Sponsors

Universitaetsklinikum Schleswig-Holstein AöR, University Hospital Schleswig-Holstein

Conditions

Post COVID Syndrome Long Covidulcerative colitis

Phase 2

A Phase II/III, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) for induction and maintenance therapy in patients with mild to moderately active ulcerative colitis

RecruitingCTIS2024-510807-13-00

Universitaetsklinikum Schleswig-Holstein AöRulcerative colitis

Start: 2024-09-12Target: 459Updated: 2025-12-17

Unknown Phase

Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS)

Not yet recruitingNCT07798570

University Hospital Schleswig-HolsteinPost COVID Syndrome Long Covid

Start: 2026-09-06End: 2028-06-30Target: 100Updated: 2026-09-01